Evidence map›Paper›PMID 35441749›Full record

ArticleCancer science2022

Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia.

Kazuki Sakatoku, Yasuhiro Nakashima, Joji Nagasaki, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Hideo Koh, Masayuki Hino, Hirohisa Nakamae

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kazuki SakatokuHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.ORCID https://orcid.org/0000-0002-2206-8693
Yasuhiro NakashimaHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.ORCID https://orcid.org/0000-0003-3025-723X
Joji NagasakiHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Mitsutaka NishimotoHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Asao HiroseHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Mika NakamaeHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Hideo KohHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Masayuki HinoHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Hirohisa NakamaeHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although ropeginterferon alfa-2b has recently been clinically applied to myeloproliferative neoplasms with promising results, its antitumor mechanism has not been thoroughly investigated. Using a leukemia model developed in immunocompetent mice, we evaluated the direct cytotoxic effects and indirect effects induced by ropeginterferon alfa-2b in tumor cells. Ropeginterferon alfa-2b therapy significantly prolonged the survival of mice bearing leukemia cells and led to long-term remission in some mice. Alternatively, conventional interferon-alpha treatment slightly extended the survival and all mice died. When ropeginterferon alfa-2b was administered to interferon-alpha receptor 1-knockout mice after the development of leukemia to verify the direct effect on the tumor, the survival of these mice was slightly prolonged; nevertheless, all of them died. In vivo CD4

Indexed as

LeukemiaMyeloproliferative DisordersNeoplasmsAnimalsCD8-Positive T-LymphocytesImmunomodulationInterferon-alphaMiceRecombinant ProteinsInterferon-alphaRecombinant Proteinsadoptive immunityantitumor effector cellsimmunomodulatory effectinterferon-alpharopeginterferon alfa-2b

Identifiers

PMID35441749
PMCPMC9277408
OpenAlexW4224226461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.